ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.840
0.00 (0.00%)
At close: Jun 18, 2025, 4:00 PM
2.860
+0.020 (0.70%)
Pre-market: Jun 20, 2025, 7:36 AM EDT
ImmunityBio Revenue
ImmunityBio had revenue of $16.52M in the quarter ending March 31, 2025, with 41,192.50% growth. This brings the company's revenue in the last twelve months to $31.22M, up 10,238.41% year-over-year. In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth.
Revenue (ttm)
$31.22M
Revenue Growth
+10,238.41%
P/S Ratio
67.53
Revenue / Employee
$45,915
Employees
680
Market Cap
2.51B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IBRX News
- 7 days ago - ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze - Seeking Alpha
- 16 days ago - ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer - Business Wire
- 17 days ago - ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors - Business Wire
- 23 days ago - ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - Business Wire
- 5 weeks ago - ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code - Business Wire
- 6 weeks ago - ImmunityBio: Getting Whiplash After FDA's Refusal To File For Anktiva's sBLA - Seeking Alpha
- 6 weeks ago - ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug - Benzinga
- 6 weeks ago - ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency's Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025 - Business Wire